{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:14:17Z","timestamp":1783718057368,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.bulcan.2023.02.025","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T12:07:43Z","timestamp":1690459663000},"page":"1168-1175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Allogreffe dans les syndromes my\u00e9lodysplasiques"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-1239","authenticated-orcid":false,"given":"Viviane","family":"Gournay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bulcan.2023.02.025_bib0255","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2023.02.025_bib0260","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2017.33","article-title":"Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs. de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium","volume":"31","author":"Zeidan","year":"2017","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.bulcan.2023.02.025_bib0265","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2013-12-542720","article-title":"Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R","volume":"123","author":"Della Porta","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2023.02.025_bib0270","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41375-018-0302-y","article-title":"Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia","volume":"33","author":"Schetelig","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bulcan.2023.02.025_bib0275","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2023.02.025_bib0280","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/leu.2015.37","article-title":"HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome\u00a0\u2013\u00a0A prospective study on behalf of SFGM-TC and GFM","volume":"29","author":"Robin","year":"2015","journal-title":"Leukemia"},{"issue":"30","key":"10.1016\/j.bulcan.2023.02.025_bib0285","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50\u201375 years of age with advanced myelodysplastic syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.bulcan.2023.02.025_bib0290","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study)","volume":"39","author":"Kr\u00f6ger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bulcan.2023.02.025_bib0305","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bulcan.2023.02.025_bib0295","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.bulcan.2023.02.025_bib0300","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","article-title":"Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation","volume":"34","author":"Della Porta","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2023.02.025_bib0310","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/leu.2017.88","article-title":"Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System","volume":"31","author":"Della Porta","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bulcan.2023.02.025_bib0315","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.bbmt.2020.07.018","article-title":"Allogeneic stem cell transplantation for patients with lower-risk myelodysplastic syndrome","volume":"26","author":"Novak","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.1016\/j.bulcan.2023.02.025_bib0320","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bulcan.2023.02.025_bib0325","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/s41375-020-0967-x","article-title":"Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?","volume":"34","author":"Robin","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bulcan.2023.02.025_bib0330","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3324\/haematol.2019.218677","article-title":"Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia","volume":"105","author":"Woo","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.bulcan.2023.02.025_bib0335","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood.2021015173","article-title":"Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis","volume":"140","author":"Robin","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2023.02.025_bib0340","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1200\/JCO.2012.46.8652","article-title":"Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis","volume":"31","author":"Koreth","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2023.02.025_bib0345","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbmt.2019.10.015","volume":"26","author":"Carr\u00e9","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2023.02.025_bib0350","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jamaoncol.2019.5140","article-title":"Comparison of patient age groups in transplantation for myelodysplastic syndrome: the Medicare Coverage With Evidence Development Study","volume":"6","author":"Atallah","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2023.02.025_bib0355","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41409-021-01502-8","article-title":"Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT","volume":"57","author":"Penack","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2023.02.025_bib0360","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/blood.2022016916","article-title":"An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients","volume":"141","author":"Sorror","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2023.02.025_bib0365","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40164-022-00328-4","article-title":"IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons\u00a0\u2265\u00a060\u00a0years with myelodysplastic syndromes","volume":"11","author":"Wu","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2023.02.025_bib0370","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"4","key":"10.1016\/j.bulcan.2023.02.025_bib0375","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/leu.2012.297","article-title":"Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia","volume":"27","author":"van Gelder","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bulcan.2023.02.025_bib0380","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23458","article-title":"Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome","volume":"88","author":"Alessandrino","year":"2013","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.bulcan.2023.02.025_bib0385","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2023.02.025_bib0390","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2016.05.026","volume":"22","author":"Potter","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2023.02.025_bib0395","doi-asserted-by":"crossref","first-page":"12342","DOI":"10.18632\/oncotarget.12511","article-title":"Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts","volume":"8","author":"Yahng","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.bulcan.2023.02.025_bib0400","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.bbmt.2018.02.007","article-title":"Improving revised international prognostic scoring system pre-allogeneic stem cell transplantation does not translate into better post-transplantation outcomes for patients with myelodysplastic syndromes: a single-center experience","volume":"24","author":"Alzahrani","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2023.02.025_bib0405","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood-2020-139492","article-title":"Safety, Efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study","volume":"136","author":"Garcia","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2023.02.025_bib0410","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/bloodadvances.2020003654","article-title":"Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors","volume":"5","author":"Grunwald","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.bulcan.2023.02.025_bib0415","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2017.03.014","article-title":"Outcomes after umbilical cord blood transplantation for myelodysplastic syndromes","volume":"23","author":"Gerds","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2023.02.025_bib0420","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"10.1016\/j.bulcan.2023.02.025_bib0425","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/bloodadvances.2017007146","article-title":"Haploidentical transplant in patients with myelodysplastic syndrome","volume":"1","author":"Robin","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.bulcan.2023.02.025_bib0430","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/leu.2012.210","article-title":"Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings","volume":"27","author":"Kr\u00f6ger","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bulcan.2023.02.025_bib0435","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbmt.2018.08.026","article-title":"HLA-mismatched donors in patients with myelodysplastic syndrome: an EBMT Registry Analysis","volume":"25","author":"Robin","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"10.1016\/j.bulcan.2023.02.025_bib0440","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC Trial)","volume":"35","author":"Kr\u00f6ger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2023.02.025_bib0445","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2023.02.025_bib0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2020.09.026","volume":"27","author":"Bejanyan","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.bulcan.2023.02.025_bib0455","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2023.02.025_bib0460","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bulcan.2023.02.025_bib0465","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.bbmt.2016.08.021","article-title":"Strategies and challenges for pharmacological maintenance therapies after allogeneic hematopoietic cell transplantation","volume":"22","author":"DeFilipp","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bulcan.2023.02.025_bib0470","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/s41409-019-0536-y","article-title":"Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"54","author":"Guillaume","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2023.02.025_bib0475","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.transci.2016.05.011","article-title":"Donor lymphocyte infusion after allogeneic stem cell transplantation","volume":"54","author":"Castagna","year":"2016","journal-title":"Transfus Apher Sci"},{"issue":"10","key":"10.1016\/j.bulcan.2023.02.025_bib0480","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.bbmt.2019.06.007","article-title":"A phase II multicenter study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplant for high-risk myelodysplasia (and older patients with acute myeloid leukemia): results of CALGB 100801 (Alliance)","volume":"25","author":"Vij","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"10.1016\/j.bulcan.2023.02.025_bib0485","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs. observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.bulcan.2023.02.025_bib0490","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.apsb.2020.06.012","article-title":"Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"10","author":"Shi","year":"2020","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"10.1016\/j.bulcan.2023.02.025_bib0495","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3324\/haematol.2017.168716","volume":"103","author":"Schmid","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bulcan.2023.02.025_bib0250","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.15898","article-title":"Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome","volume":"186","author":"Shimomura","year":"2019","journal-title":"Br J Haematol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:37:47Z","timestamp":1757792267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123002801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0007455123002801"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.02.025","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogreffe dans les syndromes my\u00e9lodysplasiques","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}